Eletriptan
drugOn this page
Also known as RelpaxUK-116,044UK-116044SID50125841SID144206290SID170465317
Summary
Eletriptan (CHEMBL1510) is an approved small-molecule serotonergic agonist (ATC N02CC06) targeting HTR1A, HTR1B, and HTR1D; indicated across 3 conditions including migraine disorder and migraine with aura.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: N02CC06
- Targets: 5 (HTR1A, HTR1B, HTR1D…)
- Indications: 3 conditions
- Clinical trials: 9
- Chemistry: 382.5 Da · C22H26N2O2S
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1510 |
| Name | Eletriptan |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 77993 |
| ChEBI | CHEBI:50922 |
| ATC | N02CC06 |
| Molecular formula | C22H26N2O2S |
| Molecular weight | 382.5 |
| InChIKey | PWVXXGRKLHYWKM-LJQANCHMSA-N |
SMILES: CN1CCC[C@@H]1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4
IUPAC name: 5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole
ChEBI definition: An N-alkylpyrrolidine, that is N-methylpyrrolidine in which the pro-R hydrogen at position 2 is replaced by a {5-[2-(phenylsulfonyl)ethyl]-1H-indol-3-yl}methyl group.
Pharmacological roles (ChEBI): serotonergic agonist, vasoconstrictor agent, non-steroidal anti-inflammatory drug.
Also known as: Eletriptan, Relpax, UK-116,044, UK-116044, SID50125841, eletriptan, SID144206290, SID170465317, ELETRIPTAN
Parent form; salt/anhydrous children: CHEMBL1201003
Patent coverage: 2,308 distinct patent families (9,393 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 9,383 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| HTR1A | 5-HT1A receptor | Full agonist | 7.4 | 0% | P08908 |
| HTR1B | 5-HT1B receptor | Full agonist | 8 | 0.2% | P28222 |
| HTR1D | 5-HT1D receptor | Full agonist | 8.9 | 0% | P28221 |
| HTR1E | 5-ht1e receptor | Full agonist | 7.2 | 0% | P28566 |
| HTR1F | 5-HT1F receptor | Full agonist | 8 | 0.1% | P30939 |
Broader ChEMBL bioactivity targets: 10 (assay-derived). Sample: Alpha-2A adrenergic receptor, 5-hydroxytryptamine receptor 1B, D(1A) dopamine receptor, Muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 1A, Muscarinic acetylcholine receptor M1, Sodium-dependent noradrenaline transporter, Mu-type opioid receptor, Sodium-dependent dopamine transporter, Histamine H3 receptor.
Bioactivity
ChEMBL activities: 6 potent at pChembl ≥ 5 of 10 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| HTR1B | 7.93 | EC50 | 11.64 | nM | CHEMBL_ACT_24416304 |
| HTR1A | 7.67 | AC50 | 21.4 | nM | CHEMBL_ACT_25164884 |
| CHRM2 | 5.38 | AC50 | 4221 | nM | CHEMBL_ACT_25195596 |
| HRH3 | 5.24 | AC50 | 5699 | nM | CHEMBL_ACT_25199392 |
| ADRA2A | 5.12 | AC50 | 7508 | nM | CHEMBL_ACT_25156289 |
| OPRM1 | 5.1 | AC50 | 8001 | nM | CHEMBL_ACT_25158035 |
Target pathways
Aggregated over 5 target gene(s): HTR1A, HTR1B, HTR1D, HTR1E, HTR1F.
Top Reactome pathways
8 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Signal Transduction | 5 | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F |
| Signaling by GPCR | 5 | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F |
| Class A/1 (Rhodopsin-like receptors) | 5 | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F |
| Amine ligand-binding receptors | 5 | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F |
| Serotonin receptors | 5 | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F |
| GPCR ligand binding | 5 | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F |
| GPCR downstream signalling | 4 | HTR1B, HTR1D, HTR1E, HTR1F |
| G alpha (i) signalling events | 4 | HTR1B, HTR1D, HTR1E, HTR1F |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| G protein-coupled receptor signaling pathway | 5 |
| G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger | 5 |
| adenylate cyclase-inhibiting serotonin receptor signaling pathway | 5 |
| chemical synaptic transmission | 5 |
| signal transduction | 5 |
| adenylate cyclase-activating G protein-coupled receptor signaling pathway | 4 |
| adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway | 4 |
| regulation of behavior | 3 |
| vasoconstriction | 2 |
| behavioral fear response | 1 |
| serotonin receptor signaling pathway | 1 |
| gamma-aminobutyric acid signaling pathway | 1 |
| positive regulation of cell population proliferation | 1 |
| regulation of serotonin secretion | 1 |
| regulation of vasoconstriction | 1 |
Indications & clinical
Indications
3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| migraine disorder | 4 | MONDO:0005277 | MONDO:0005277 |
| migraine with aura | 3 | MONDO:0005475 | MONDO:0005475 |
| migraine without aura | 3 | MONDO:0100431 | MONDO:0100431 |
Clinical trials
Total trials: 9.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 4 |
| PHASE3 | 4 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00174395 | PHASE4 | COMPLETED | A Trial to Study of the Effects of Eletriptan 40mg on Mild vs Moderate to Severe Pain Intensity of Migraine |
| NCT00259649 | PHASE4 | COMPLETED | Prospective Survey of Menstrual Migraine & Prevention With Eletriptan |
| NCT00632385 | PHASE4 | COMPLETED | Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy |
| NCT00634985 | PHASE4 | COMPLETED | Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory Drugs |
| NCT01978496 | PHASE3 | COMPLETED | Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine |
| NCT01986088 | PHASE3 | COMPLETED | Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study |
| NCT01986270 | PHASE3 | COMPLETED | Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo |
| NCT01989936 | PHASE3 | COMPLETED | Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan |
| NCT00751803 | PHASE2 | COMPLETED | BI 44370 TA in Acute Migraine Attack |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 7 variant annotation(s) for this drug (gene-keyed; see PharmGKB).
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
415 molecules share ≥1 primary target. Top 60 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| DIHYDROERGOTAMINE | ChEMBL + PubChem | Phase 4 (approved) | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F |
| ERGOTAMINE | ChEMBL + PubChem | Phase 4 (approved) | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F |
| IMIPRAMINE | ChEMBL + PubChem | Phase 4 (approved) | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F |
| NARATRIPTAN | ChEMBL + PubChem | Phase 4 (approved) | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F |
| RISPERIDONE | ChEMBL + PubChem | Phase 4 (approved) | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F |
| RIZATRIPTAN | ChEMBL + PubChem | Phase 4 (approved) | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F |
| SUMATRIPTAN | ChEMBL + PubChem | Phase 4 (approved) | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F |
| ZOLMITRIPTAN | ChEMBL + PubChem | Phase 4 (approved) | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F |
| SEROTONIN | ChEMBL + PubChem | Phase 3 (approved) | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F |
| YOHIMBINE | ChEMBL + PubChem | Phase 3 (approved) | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F |
| MEBUFOTENIN | ChEMBL | Phase 2 | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F |
| CLOZAPINE | ChEMBL + PubChem | Phase 4 (approved) | HTR1A, HTR1B, HTR1E, HTR1F |
| OLANZAPINE | ChEMBL + PubChem | Phase 4 (approved) | HTR1A, HTR1B, HTR1E, HTR1F |
| BREXPIPRAZOLE | ChEMBL | Phase 4 (approved) | HTR1A, HTR1B, HTR1D, HTR1E |
| FROVATRIPTAN | ChEMBL | Phase 4 (approved) | HTR1A, HTR1B, HTR1D, HTR1E |
| PSILOCIN | ChEMBL | Phase 2 | HTR1A, HTR1B, HTR1D, HTR1E |
| CYPROHEPTADINE | ChEMBL + PubChem | Phase 4 (approved) | HTR1A, HTR1E, HTR1F |
| LASMIDITAN | ChEMBL + PubChem | Phase 4 (approved) | HTR1D, HTR1E, HTR1F |
| METHYLERGONOVINE | ChEMBL + PubChem | Phase 4 (approved) | HTR1A, HTR1E, HTR1F |
| PRAMIPEXOLE | ChEMBL + PubChem | Phase 4 (approved) | HTR1A, HTR1B, HTR1E |
| QUETIAPINE | ChEMBL + PubChem | Phase 4 (approved) | HTR1A, HTR1E, HTR1F |
| SORAFENIB | ChEMBL + PubChem | Phase 4 (approved) | HTR1A, HTR1E, HTR1F |
| ARIPIPRAZOLE | ChEMBL | Phase 4 (approved) | HTR1A, HTR1B, HTR1D |
| AZELASTINE | ChEMBL | Phase 4 (approved) | HTR1B, HTR1D, HTR1E |
| CARIPRAZINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR1B, HTR1D |
| KETANSERIN | ChEMBL | Phase 4 (approved) | HTR1A, HTR1B, HTR1D |
| NEFAZODONE | ChEMBL | Phase 4 (approved) | HTR1A, HTR1B, HTR1D |
| OXYMETAZOLINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR1B, HTR1D |
| SALMETEROL | ChEMBL | Phase 4 (approved) | HTR1A, HTR1B, HTR1D |
| SILODOSIN | ChEMBL | Phase 4 (approved) | HTR1A, HTR1B, HTR1D |
| VILAZODONE | ChEMBL | Phase 4 (approved) | HTR1A, HTR1B, HTR1D |
| XYLOMETAZOLINE | ChEMBL | Phase 4 (approved) | HTR1A, HTR1B, HTR1D |
| ACETRYPTINE | ChEMBL | Phase 2 | HTR1A, HTR1B, HTR1D |
| GSK163090 | ChEMBL | Phase 2 | HTR1A, HTR1B, HTR1D |
| LYSERGIDE | ChEMBL | Phase 2 | HTR1A, HTR1D, HTR1E |
| RITANSERIN | ChEMBL | Phase 2 | HTR1A, HTR1B, HTR1E |
| ASENAPINE | ChEMBL + PubChem | Phase 4 (approved) | HTR1A, HTR1E |
| CANNABIDIOL | ChEMBL + PubChem | Phase 4 (approved) | HTR1A, HTR1E |
| PALIPERIDONE | ChEMBL + PubChem | Phase 4 (approved) | HTR1B, HTR1D |
| ZIPRASIDONE | ChEMBL + PubChem | Phase 4 (approved) | HTR1A, HTR1E |
| CINACALCET | ChEMBL | Phase 4 (approved) | HTR1A, HTR1D |
| LOPERAMIDE | ChEMBL | Phase 4 (approved) | HTR1A, HTR1D |
| MIANSERIN | ChEMBL | Phase 4 (approved) | HTR1A, HTR1D |
| PINDOLOL | ChEMBL | Phase 4 (approved) | HTR1A, HTR1B |
| PRAZOSIN | ChEMBL | Phase 4 (approved) | HTR1A, HTR1D |
| SERTINDOLE | ChEMBL | Phase 4 (approved) | HTR1A, HTR1B |
| TEGASEROD | ChEMBL | Phase 4 (approved) | HTR1A, HTR1D |
| LATREPIRDINE | ChEMBL | Phase 3 | HTR1D, HTR1E |
| ALNIDITAN | ChEMBL | Phase 2 | HTR1A, HTR1D |
| MAZAPERTINE | ChEMBL | Phase 2 | HTR1A, HTR1B |
| NIGULDIPINE | ChEMBL | Phase 2 | HTR1A, HTR1B |
| PENFLURIDOL | ChEMBL | Phase 2 | HTR1A, HTR1D |
| SPIRAMIDE | ChEMBL | Phase 2 | HTR1A, HTR1D |
| ACEMETACIN | ChEMBL | Phase 4 (approved) | HTR1A |
| ACETOPHENAZINE | ChEMBL | Phase 4 (approved) | HTR1A |
| ACETYLCHOLINE | ChEMBL | Phase 4 (approved) | HTR1A |
| ALMOTRIPTAN | ChEMBL | Phase 4 (approved) | HTR1A |
| AMILORIDE | ChEMBL | Phase 4 (approved) | HTR1A |
| AMITRIPTYLINE | ChEMBL | Phase 4 (approved) | HTR1A |
| AMLODIPINE | ChEMBL | Phase 4 (approved) | HTR1A |
Related Atlas pages
- Genes: HTR1A, HTR1B, HTR1D, HTR1E, HTR1F
- Diseases: migraine disorder, migraine with aura, migraine without aura
- Drugs: Dihydroergotamine, Ergotamine, Imipramine, Naratriptan, Risperidone, Rizatriptan, Sumatriptan, Zolmitriptan, Serotonin, Yohimbine, Clozapine, Olanzapine, Brexpiprazole, Frovatriptan, Cyproheptadine, Lasmiditan, Methylergonovine, Pramipexole, Quetiapine, Sorafenib, Aripiprazole, Azelastine, Cariprazine, Ketanserin, Nefazodone, Oxymetazoline, Salmeterol, Silodosin, Vilazodone, Xylometazoline, Asenapine, Cannabidiol, Paliperidone, Ziprasidone, Cinacalcet, Loperamide, Mianserin, Pindolol, Prazosin, Sertindole, Tegaserod, Latrepirdine, Acemetacin, Acetophenazine, Acetylcholine, Almotriptan, Amiloride, Amitriptyline, Amlodipine